地舒单抗治疗儿童原发性骨质疏松症一例
本文报告一例13.5岁男孩患严重原发性骨质疏松症伴多发椎体畸形,予地舒单抗60 mg皮下注射每3个月一次治疗30个月。治疗后背痛6周内消失,腰椎和股骨颈骨密度分别增加65.6%和25.3%,椎体形态恢复正常,线性生长未受损,第二年出现短暂高钙血症。
要点
- 地舒单抗60 mg每3个月一次治疗儿童原发性骨质疏松症可显著改善骨密度和椎体形态。
- 治疗期间需监测血钙,警惕短暂高钙血症,尤其在减停药物和青春期生长突增时。
- 地舒单抗可能成为儿童原发性骨质疏松症的治疗选择,但需更多研究验证。
核心结论
- 地舒单抗在本例儿童原发性骨质疏松症中临床和影像学效果显著。
研究设计与样本
- 个案报告:一例13.5岁初治男孩,严重骨质疏松伴多发椎体畸形,排除继发原因及已知骨脆性基因异常。
主要发现
- 地舒单抗60 mg皮下注射每3个月一次治疗30个月,首次注射后6周内疼痛消失。
- 腰椎骨密度增加65.6%,股骨颈骨密度增加25.3%,变形椎体恢复正常形态,线性生长未受损。
- 治疗第二年注射前出现短暂高钙血症,最高3.09 mmol/l。
关键数值与推荐
- 地舒单抗剂量60 mg皮下注射,每3个月一次,疗程30个月。
- 腰椎骨密度增幅65.6%,股骨颈骨密度增幅25.3%。
- 高钙血症最高3.09 mmol/l,发生于注射前。
临床怎么用
- 地舒单抗可用于儿童原发性骨质疏松症,但需密切监测血钙和骨密度变化。
- 注意青春期生长突增和药物减停可能诱发高钙血症。
局限性
- 仅一例个案报告,结论不能推广至所有儿童原发性骨质疏松症患者。
- 高钙血症机制为推测性,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary osteoporosis is rare in children and adolescents and its optimal pharmacological management is uncertain. Bisphosphonates are commonly used while denosumab has only been administered to a few children with osteogenesis imperfecta. We studied a treatment-naïve 13.5-year-old boy with severe osteoporosis and multiple vertebral deformities who presented with back pain and difficulty in walking. Causes of secondary osteoporosis were excluded and there were no abnormalities in genes known to cause bone fragility. He was treated with denosumab 60 mg subcutaneously every 3 months for 30 months, and he was pain-free within 6 weeks after the first injection. Lumbar spine BMD and femoral neck BMD increased with treatment by 65.6% and 25.3%, respectively, and deformed vertebrae regained their normal shape; linear growth was not impaired. During the second year of treatment, transient hypercalcemia (maximum 3.09 mmol/l) before the denosumab injection was observed. In conclusion, denosumab was highly effective in this case of primary pediatric osteoporosis, with remarkable clinical and radiological response. Transient hypercalcemia was probably due to amplification of the effect of growth spurt and puberty on bone remodeling by the transient, short-term discontinuation of the drug. Furthermore, our data suggest that mobilization of calcium from treatment-induced sclerotic transverse lines in bone metaphyses may contribute to the development of hypercalcemia.
引用
- Anastasilakis AD, Makras P, Doulgeraki A, et al. Denosumab for the treatment of primary pediatric osteoporosis. Osteoporos Int. 2021. PMID: 33987688. doi:10.1007/s00198-021-06002-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。